企业重整

Search documents
*ST仁东重整执行完毕 2025年一季度净资产转正
Zheng Quan Shi Bao Wang· 2025-04-29 02:28
Core Viewpoint - *ST Rendo has successfully completed its restructuring process, resolving historical debt issues and optimizing its asset-liability structure, which positions the company for sustainable growth in the third-party payment industry [1][2]. Financial Performance - In 2024, *ST Rendo achieved a revenue of 1.159 billion yuan, while in the first quarter of 2025, the revenue was 202 million yuan, with a net profit of 485 million yuan [1]. - As of the first quarter of 2025, the company's consolidated net assets turned positive, amounting to approximately 878 million yuan [1]. Restructuring Process - The restructuring journey began on May 7, 2024, initiated by creditors due to the company's inability to repay debts, leading to a formal application for restructuring [1]. - The Guangzhou Intermediate People's Court accepted the restructuring application on December 30, 2024, and approved the restructuring plan on February 18, 2025 [2]. - The restructuring plan was executed successfully by March 18, 2025, with the involvement of strong investors such as CITIC Capital and Guangzhou Asset Management [2]. Business Strategy and Future Plans - Following the restructuring, *ST Rendo plans to utilize surplus funds to increase the capital of its subsidiary, Heli Technology, by 200 million yuan, raising its registered capital to 300 million yuan [3]. - This capital increase aligns with regulatory requirements and the company's strategic goals, enhancing Heli's competitive strength in the third-party payment sector [3]. - The company aims to focus on its core business in third-party payments, improve its credit system, and expand cross-border business opportunities for sustainable development [1][3].
人福医药集团股份公司 关于控股股东重整案重整计划获得法院批准的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-04-27 08:18
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:600079 证券简称:人福医药 编号:临2025-044号 人福医药集团股份公司 关于控股股东重整案重整计划获得法院批准的公告 特 别 提 示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容 的真实性、准确性和完整性承担法律责任。 人福医药集团股份公司(以下简称"公司"或"人福医药")于2024年10月1日披露了《人福医药集团股份 公司关于法院裁定受理控股股东重整暨指定管理人的公告》(公告编号:临2024-102号),湖北省武汉 市中级人民法院(以下简称"武汉中院")于2024年9月30日裁定受理武汉当代科技产业集团股份有限公 司(以下简称"当代科技")重整,并于同日指定武汉当代科技产业集团股份有限公司清算组担任当代科 技管理人。 经审查,当代集团公司重整计划草案具备《中华人民共和国企业破产法》第八十一条规定的全部内容, 其债权分类及债权清偿顺序符合法律规定;依据债务人财产状况、审计评估结论、重整投资人投资情 况,对出资人权益和债权所做的调整以及调整后的债权受偿方案,兼顾了各类债权人利益,不违背法律 规定 ...